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Numerous case reports and retrospective studies suggest an association between M.
pneumoniae respiratory infection and extrapulmonary complications, the most common of
which involve the central nervous system. There is insufficient evidence based on prospective,
carefully controlled observations to confirm this association at the present time. A variety of
mechanisms has been suggested to explain the involvement of distant organ systems. These in-
clude metastatic infection, autoimmunity, toxin generation, and altered host immunity. While
none of these is based on evidence to prove an association, the state of anergy which accom-
panies M. pneumoniae pneumonia deserves consideration and further study as the most plausi-
ble link between infecting organisms and extrapulmonary manifestations.
EVIDENCE OF ASSOCIATION BETWEEN M. PNEUMONIAE
INFECTION AND CENTRAL NERVOUS SYSTEM DISEASE
Epidemiology
Extrarespiratory manifestations have been associated with Mycoplasma pneu-
moniae infections since Hobart Reiman described neurologic complications in two
patients with primary atypical pneumonia in 1938 [1]. Yesnick reviewed this associa-
tion in 1956 and added one case to the then-existing 38 reports in the literature [2].
Hodges added four case reports in 1972, and in 1973 Lehrer and Kalavsky reviewed
50 reported cases and added five of their own [3,4]. While a variety of ex-
trapulmonary syndromes have been associated with Mycoplasmapneumoniae, cen-
tral nervous system (CNS) findings are the most frequently reported [5]. Biberfeld's
collection of seven patients with well-documented M. pneumoniae pneumonia and
neurologic disease is the most impressive example of this association [6]. Since
neurologic complications are clinically the most significant and apparent, they will
be the focus of this paper.
In addition to case reports and retrospective reviews, two prospective studies have
addressed the association of extrarespiratory symptoms and mycoplasma infection.
Foy reported no cases among 462 patients with M. pneumoniae pneumonia collected
in Seattle over a five-year period [7]. Lind collected 371 patients with CNS findings
over a 4¼2-year period and found evidence based upon serologic analysis of concur-
rent M. pneumoniae infection in 19 (5 percent), a higher figure than predicted for
the incidence of mycoplasma infection in the general population [8].
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Taken together, these reports suggest an association between M. pneumoniae
respiratory infection and neurologic disease. Ponka has reviewed the literature and
reported studies of his own from Finland [5]. He estimates the frequency of
associated CNS complications to be as high as 4.8 percent but notes that biased
selection of cases and non-specificity of serologic reactions employed for diagnosis
may have influenced these figures. Other extrarespiratory disease manifestations
such as arthritis and carditis occurred somewhat less frequently. If such complica-
tions occur in 1 to 5 percent ofall patients withM. pneumoniaeinfection, one would
have expected several cases of neurologic disease, arthritis, or carditis to have been
observed in the Seattle study reported by Foy and colleagues. If the frequency is as
low as 0.1 percent as suggested by Yesnick [2], a prospective study would need to ac-
cumulate several thousand subjects to yield statistical validity.
Isolation of Organismsfrom Extrapulmonary Sites
Scattered reports of direct isolation of M. pneumoniae from blood and
cerebrospinal fluid (CSF) have accumulated to support the association of CNS
disease with pneumonic infection. Bayer et al. reported evidence ofM. pneumoniae
in CSF and blood of a man with serologically positive Mycoplasmapneumoniae and
Guillain-Barre syndrome [9]. Although cultures of CSF and buffy coat from
peripheral blood were negative, metabolic activity attributable to mycoplasmas was
detected by measuring uridine-to-uracil uptake ratios. Such activity, attributed to
M. pneumoniae by indirect immunofluorescence of inoculated tissue culture cells,
was detected on the thirtieth and fifty-fourth days of convalescence, suggesting the
organism persistently infected the nervous system for nearly two months. This
study, together with other scattered reports of M. pneumoniae isolations from ex-
trapulmonary sites [10,11,12], must be considered inconclusive until confirmed by
isolation and identification of mycoplasma organisms from extrapulmonary sites in
similar cases.
Autoantibodies
The presence ofautoantibodies to brain and other host tissues has suggested a link
between Mycoplasmapneumoniae and extrapulmonary disease. Such antibodies are
produced during mycoplasma pneumonia and most evidence would suggest they
are stimulated by antigens cross-reactive with host tissues, such as the I antigen on
erythrocytes and glycolipids in brain tissue. Such antibodies to host tissues have
been known since the early descriptions of primary atypical pneumonia, and their
common occurrence with uncomplicated M. pneumoniae pneumonia would suggest
they are not pathogenic for the host in most instances. Rare cases of autoimmune
hemolytic anemia have been associated with M. pneumoniae infection. Biberfeld's
careful study of the association of antibrain antibodies and CNS disease revealed
that 80 percent of controls without CNS manifestations had the same type of an-
tibodies [6].
In summary, the evidence of a causal association between M. pneumoniae
respiratory infection and extrapulmonary disease, particularly of the CNS, is sug-
gestive but not conclusive. Accumulation of more well-documented cases and a
stronger epidemiologic association is necessary before organism and disease
manifestations can be considered unquestionably linked.
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POSSIBLE MECHANISMS LINKING M. PNEUMONIAE
INFECTION AND CNS DISEASE
Direct Invasion ofOrganisms
Given the possibility of this association, what might the mechanisms of interac-
tion be? The nature ofM. pneumoniae respiratory disease does not suggest that ex-
trapulmonary invasion is likely to occur [13]. The organism is known to attach to the
external surface ofciliated mucosal cells, and submucosal penetration is not evident
in the experimental animals which have been studied. Neither is systemic escape of
M. pneumoniae observed in immunosuppressed animals [14]. Nevertheless,
organisms have been cultured from blood ofpatients [11] and, as mentioned above,
from spinal fluid [10]. Thus, direct invasion cannot be ruled out. Proofofthis mode
of pathogenesis would require additional well-documented isolations from spinal
fluid or central nervous system tissue as well as evidence of local pathology due to
infection. Further careful study of cases, utilizing the more sensitive metabolic
detection methods, in addition to culture on standard inert media and tissue culture
systems, will be necessary to confirm this proposed etiology of mycoplasma-
associated CNS disease.
Generation of Toxins
Another mechanism by which Mycoplasma pneumoniae in the lung could cause
distant CNS manifestations might be through the effect of a soluble toxin. Animal
models for this phenomenon are to be found in rolling disease ofmice, caused byM.
neurolyticum, and cerebral arteritis due to M. gallisepticum in turkeys; in the latter
case, direct infection of cerebral vessels is required to produce disease [15]. M.
pneumoniae has the ability to lyse red blood cells by generating peroxide, but direct
attachment of mycoplasma to erythrocyte is required. Also, the metabolic dysfunc-
tion and disruption ofcell structure produced byM. pneumoniaein tracheal cultures
requires attachment ofthe organism to ciliated epithelial cells [16]. No evidence of a
distant toxic effect has been found for M. pneumoniae.
Autoimmunity
A third mechanism proposed to link M. pneumoniae infection and distant CNS
disease is the production of autoantibodies. Since a variety of antibodies to host
tissues is characteristic ofmycoplasma pneumonia, this has been a popular concept.
The mechanism by which antibodies to host antigens are formed is not clear, but it is
known that infectious agents may modify host tissues and induce autoantibodies.
The normal T-lymphocyte suppression of self-immunity can be bypassed by cross-
reacting antigens, alteration of host cell antigen by the infecting organism, and non-
specific activation of lymphocytes by microbial mitogens. All of these activities are
theoretically possible inM. pneumoniae infections (as discussed in Symposium VIII:
Mycoplasma interactions with lymphocytes and phagocytes). While the presence of
autoantibodies is obvious, direct evidence of antibody-mediated injury such as
glomerulonephritis or other evidence of immune complex disease has not been
described. Biberfeld reported indirect evidence of circulating immune complexes in
patients with mycoplasma pneumonia, but this observation has not been confirmed
by others [17]. It should also be noted that autoantibodies are present to varying
degrees in many human disease states and are more often a secondary manifestation
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a tendency to chronicity and a high frequency of certain histocompatability types
have not been associated with extrapulmonary complications of Mycoplasma
pneumoniae infection. Rather, patients have tended to suffer acute manifestations
over a short course and, pending survival ofthe initial illness, tend not to suffer pro-
gressive deterioration. Thus, while autoimmunity cannot be excluded, it appears less
likely than other alternatives under consideration.
Immunosuppression
Recent advances in defining the immunologic interactions between mycoplasmas
and the immune system suggest organism-induced immunosuppression as a
mechanism linking extrapulmonary complications with the primary respiratory
disease. Biberfeld's observations of anergy to tuberculin skin testing and depressed
lymphocyte responses to M. pneumoniae antigen during convalescence from acute
pneumonia suggest that this is a regular feature of Mycoplasmapneumoniae infec-
tions [18]. These findings have been confirmed by Sabato et al., who demonstrated
depressed stimulation of peripheral lymphocytes by PHA and pokeweed mitogens
but not by Concanavalin A [19]. They interpret these results to show a selective
decrease in B-lymphocyte function during Mycoplasma pneumoniae infection.
Whether perturbations ofT-lymphocyte suppressor or helper subsets are responsible
for this state of immunosuppression remains to be investigated.
Such altered immune responsiveness during mycoplasma infections could be the
permissive factor for several of the associated phenomena under discussion. The
escape of organisms from lung tissues to systemic sites, the generation of autoan-
tibodies, and the reported prolonged carriage of organisms in affected tissues could
all be facilitated by such a state of anergy. One might even speculate that otherwise
quiescent infections of the central nervous system could become activated and pro-
duce clinically significant disease manifestations. All of this is, of course, conjec-
tural but certainly careful studies of the immune sta-tus of subjects with M.
pneumoniae pneumonia, with and without extrapulmonary manifestations, are in-
dicated before a link between these entities can be established.
SUMMARY AND CONCLUSIONS
In summary, I would like to emphasize the following points relative to this discus-
sion of the nature of associated M. pneumoniae infection and CNS disease:
1. That clinical reports suggest an association but that confirmation is lacking
at the present time.
2. That altered immune reactivity of the infected host should be considered a
possible link between the infecting organism and extrapulmonary complica-
tions.
3. That there is a real need for careful study of well-documented cases for
evidence of circulating organisms, antigenemia, immune complexes,
evidence of localized infection, histopathology, or immunopathology. Only
direct evidence, such as culture and identification of organisms and iden-
tification of antigen-antibody complexes should be sought, since indirect
evidence is abundant but inconclusive. Such studies should also include a
careful dissection of the components ofthe immune response of the infected
host to the infecting mycoplasma for evidence of suppression as well as
stimulation of immunity.
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4. Solution of this complex problem would not only enlighten those interested
in human mycoplasmology, it would also provide information relative to the
pathogenesis of other infectious diseases in which the infecting organism in-
duces non-specific as well as specific alterations of the host's immune
resDonse.
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